Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Guangzhou Zhiyi Biotechnology

Request full access

Focuses on the research and development of second-generation probiotics and Live Biotherapeutics

Guangzhou, ChinaFounded 2013Biotech & Life Sciences

About Guangzhou Zhiyi Biotechnology

Guangzhou Zhiyi Biotechnology Co., Ltd., established in 2013, operates as a clinical-stage biopharmaceutical company focused on the development of Live Biotherapeutic Products (LBPs) and next-generation probiotics. The company was co-founded by Dr. Zifachao, a prominent expert in digestive diseases, and Liu Yangyang, whose doctoral research on a specific strain of Bacteroides fragilis, named SK08, laid the foundational science for the company. This initial discovery highlighted the potential of the bacterium in treating digestive disorders.

The firm has strategically positioned itself in the emerging field of microbiome-based therapeutics, building a comprehensive platform that spans from the initial discovery of novel functional bacterial strains to late-stage clinical development and commercial-scale manufacturing. This integrated system allows for research into the relationship between the human microbiome and diseases, target identification, and the subsequent development of LBP candidates. The company's business model is centered on the research, development, and eventual commercialization of proprietary microbial-based drugs and also encompasses a business segment for health foods and ordinary foods.

Zhiyi Biotechnology's lead product candidate, SK08, is a live biotherapeutic developed from a proprietary strain of *Bacteroides fragilis*. This product is notable for being China's first domestically developed LBP to enter clinical trials. SK08 is primarily being investigated for the treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D), with a Phase III clinical trial underway. The company is also exploring SK08's efficacy in combination with PD-1 inhibitors for advanced solid tumors and for treating mild to moderate ulcerative colitis. Another significant pipeline candidate is SK10, an inactivated version of *Bacteroides fragilis*, which has completed a Phase 1 clinical trial in the U.S. for treating chemotherapy-induced diarrhea.

Since its inception, the company has secured significant funding to advance its clinical pipeline. It has completed multiple financing rounds, including a Series C in March 2024, raising a total of over $45 million from investors such as SDIC Venture Capital, Guangdong Investment, and KIP Capital. Headquartered in Guangzhou, the company has a research and development center and two GMP-standard pilot production workshops to support its clinical and future commercial activities. The company is led by CEO Ye Wang and Chairman Xiaohui Wang.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2013
Headquarters
Guangzhou, China
Employees
6
Open positions
None listed
Dealroom signal
53.5/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES COther financing Mar 2024 $14M $55M Guangdong Technology Financial Group · Airui Investment ↗
SERIES BOther financing Jul 2022 $15M $60M SDIC Venture Capital · Helichuangxing Group · GDD Fund ↗
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Guangzhou Zhiyi Biotechnology website traffic

Latest recorded traffic for Guangzhou Zhiyi Biotechnology is 680 monthly website visits, up 277.8% over the last three months. Guangzhou Zhiyi Biotechnology's team grew 0% over the past year.

Latest monthly visits680 3-month web change+277.8% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Guangzhou Zhiyi Biotechnology in the Guangzhou ecosystem

Live from Dealroom

The Guangzhou Zhiyi Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Hejun Capital

Series A3 investors entered at this stage

  • SDIC Venture Capital
  • Helichuangxing Group
  • GDD Fund

Series B and later2 investors entered at this stage

  • Guangdong Technology Financial Group
  • Airui Investment

Other known investors1 additional known investor

  • Southern Medical University
Employees 6 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇳 China100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Guangzhou Zhiyi Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Guangzhou Zhiyi Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.